Purchase Order HHSN261201800062P

<p>The National Cancer Institute issued a $13,043.75 delivery order to Illumina, Inc. on August 17, 2018, for genetic sequencing and genomic analysis technologies.</p> <p>Place of performance is Bethesda, MD. The order has a firm fixed-price pricing structure and an ultimate completion date of September 15, 2018. Illumina manufactures advanced DNA and RNA sequencing instruments, reagents, consumables, and bioinformatics software supporting genomic research across federal agencies.</p>

<p>The National Cancer Institute issued a $13,043.75 delivery order to Illumina, Inc. on June 20, 2018, for genetic sequencing and genomic analysis technologies. Place of performance is Bethesda, MD. Ultimate completion date is July 19, 2018.</p> <p>The source does not identify the parent vehicle under which this delivery order was issued.</p>

<p>The National Cancer Institute issued a delivery order to Illumina, Inc. on July 23, 2015, with a ceiling value of $24,772.41 for genomic sequencing equipment and reagents.</p> <p>Place of performance is Baltimore, Maryland. The order was firm fixed price with no set-aside. Ultimate completion date was April 12, 2020.</p>

<p>The National Cancer Institute awarded a purchase order to Novogene Corporation Inc. for $13,835.00 on March 21, 2018, for pre-prepared DNA library sequencing using Illumina NovaSeq PE150 technology. Work is performed in Bethesda, Maryland, with an ultimate completion date of May 20, 2018. The order carries firm fixed price terms and no set-aside designation. Novogene is a minority-owned small business.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for sequencing services valued at $14,558.16, issued on January 14, 2020, with final completion due February 12, 2020. Work is performed in Bethesda, Maryland. The order carries firm fixed pricing and no set-aside designation.</p>

<p>The National Cancer Institute issued a delivery order to Illumina, Inc. on October 23, 2017, with a ceiling value of $6,892.55. Place of performance is Bethesda, MD. The order is for genetic sequencing equipment, reagents, or consumables consistent with Illumina's portfolio of DNA and RNA sequencing instruments and bioinformatics software supporting genomic research. The ultimate completion date is November 19, 2017. The order is priced as firm fixed price with no set-aside designation.</p>

<p>The National Cancer Institute issued a delivery order to Illumina, Inc. on June 26, 2018, with a ceiling value of $13,043.75 and an ultimate completion date of July 26, 2018.</p> <p>Place of performance is Bethesda, MD 20892. The order is priced on a firm fixed-price basis with no set-aside designation. The delivery order procures genetic sequencing equipment, reagents, consumables, or related bioinformatics services from Illumina's portfolio of genomic analysis technologies.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $20,987.00 on August 31, 2017, with final completion scheduled for March 19, 2018. Performance takes place in Bethesda, Maryland. The order covers sequencing instruments, reagents, consumables, or bioinformatics software—Illumina's core product portfolio for federal genomic research applications. Pricing is firm fixed price with no set-aside applied.</p>

<p>The National Cancer Institute issued a delivery order to Illumina, Inc. on September 7, 2017, with a ceiling value of $6,700.18.</p> <p>Place of performance is Bethesda, MD 20892. The order has a firm fixed-price structure and an ultimate completion date of October 8, 2017. The delivery order calls for genetic sequencing equipment, reagents, consumables, or bioinformatics software consistent with Illumina's portfolio of DNA and RNA sequencing instruments and analytical tools.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. valued at $16,362.77 on February 26, 2020, for a service agreement with a firm fixed price. Work is performed in Bethesda, Maryland, with an ultimate completion date of May 31, 2020. The order procures sequencing-related services or equipment from Illumina's portfolio of genomic analysis technologies and associated support.</p>